An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link
- PMID: 10201630
An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link
Abstract
Human high-grade gliomas (HGG) are one of the most devastating human malignancies. They are rapidly progressing heterogenous tumors for which no curable treatment is available. Although these tumors are believed to be of glial cell origin, known tumor-specific markers do not characterize them. The specific environmental conditions that cause or promote the development of HGG are not known. The pathomechanism of HGG is yet to be revealed, although more specific genetic alterations are assigned to HGG. Recently, we have found that HGG overexpress a receptor for an immune regulatory cytokine, interleukin-13 (IL-13). In fact, it appears that all patients with glioblastoma multiforme may possess this receptor. IL-13 is an antiinflammatory cytokine with many overlapping functions to its homologue, IL-4. There is a high degree of specificity of the overexpression of the IL-13 receptor in HGG. This receptor is not only quantitatively but also qualitatively different from the only known functional signaling receptor for IL-13 of normal tissue. It is not shared with IL-4. The more restrictive receptor for IL-13 thus may represent a new factor specific for a disease as heterogenous as HGG.
Similar articles
-
Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.Clin Cancer Res. 1999 May;5(5):985-90. Clin Cancer Res. 1999. PMID: 10353730
-
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.Cancer Res. 2004 Dec 15;64(24):9160-6. doi: 10.1158/0008-5472.CAN-04-0454. Cancer Res. 2004. PMID: 15604287
-
Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors.Cancer. 2004 Sep 1;101(5):1036-42. doi: 10.1002/cncr.20470. Cancer. 2004. PMID: 15329913
-
Differential responses of human monocytes and macrophages to IL-4 and IL-13.J Leukoc Biol. 1999 Oct;66(4):575-8. J Leukoc Biol. 1999. PMID: 10534111 Review.
-
Cancer genetics/epigenetics and the X chromosome: possible new links for malignant glioma pathogenesis and immune-based therapies.Crit Rev Oncog. 2000;11(1):77-95. Crit Rev Oncog. 2000. PMID: 10795628 Review.
Cited by
-
Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.J Neurooncol. 2003 Oct;65(1):63-75. doi: 10.1023/a:1026238331739. J Neurooncol. 2003. PMID: 14649886 Review.
-
A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.Neuro Oncol. 2012 Oct;14(10):1239-53. doi: 10.1093/neuonc/nos211. Epub 2012 Sep 5. Neuro Oncol. 2012. PMID: 22952195 Free PMC article.
-
Receptor-Targeted Glial Brain Tumor Therapies.Int J Mol Sci. 2018 Oct 25;19(11):3326. doi: 10.3390/ijms19113326. Int J Mol Sci. 2018. PMID: 30366424 Free PMC article. Review.
-
IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13.Neoplasia. 2002 Sep-Oct;4(5):388-99. doi: 10.1038/sj.neo.7900234. Neoplasia. 2002. PMID: 12192597 Free PMC article.
-
When better still might not be good enough.Transl Cancer Res. 2017 Oct;6(Suppl 7):S1244-S1247. doi: 10.21037/tcr.2017.09.40. Transl Cancer Res. 2017. PMID: 30214854 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical